Replies to post #37244 on Regen BioPharma Inc (RGBP)

[centsability4me]

it's a fake rumor
look @ my earlier post .
If he had passed away last week , then they wouldn't have PRed his presentation date for the 4th , on the 3rd.

https://www.accesswire.com/574973/FibroGenesis-to-Present-at-LSX-World-Congress-in-London-UK

FibroGenesis to Present at LSX World Congress in London, UK
Monday, February 3, 2020 8:48 AM

HOUSTON, TX / ACCESSWIRE / February 3, 2020 / FibroGenesis, a Texas-based regenerative medicine company focused on tissue regeneration and chronic disease reversal using Human Dermal Fibroblasts (HDFs), today announced that Pete O'Heeron, FibroGenesis's Chief Executive Officer and Tom Ichim, PhD, Chief Scientific Officer, will present at the LSX World Congress on Tuesday, February 4, 2020 at 11:45AM in London, UK.

In their presentation, Mr. O'Heeron and Dr. Ichim will discuss FibroGenesis's chronic disease pipeline and the clinical benefits of using its proprietary fibroblast technology as a cell source to reverse these diseases. The company is preparing for continued clinical trials and development after receiving FDA clearance of its Investigational New Drug protocol.

[centsability4me]

it's a fake rumor
look @ my earlier post .
If he had passed away last week , then they wouldn't have PRed his presentation date for the 4th , on the 3rd.

https://www.accesswire.com/574973/FibroGenesis-to-Present-at-LSX-World-Congress-in-London-UK

FibroGenesis to Present at LSX World Congress in London, UK
Monday, February 3, 2020 8:48 AM

HOUSTON, TX / ACCESSWIRE / February 3, 2020 / FibroGenesis, a Texas-based regenerative medicine company focused on tissue regeneration and chronic disease reversal using Human Dermal Fibroblasts (HDFs), today announced that Pete O'Heeron, FibroGenesis's Chief Executive Officer and Tom Ichim, PhD, Chief Scientific Officer, will present at the LSX World Congress on Tuesday, February 4, 2020 at 11:45AM in London, UK.

In their presentation, Mr. O'Heeron and Dr. Ichim will discuss FibroGenesis's chronic disease pipeline and the clinical benefits of using its proprietary fibroblast technology as a cell source to reverse these diseases. The company is preparing for continued clinical trials and development after receiving FDA clearance of its Investigational New Drug protocol.

[gotinearly]

Unreal, what a flat out lie.